Phase 2 N=24 Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer
Prostate Cancer
Primary: Uptake and Retention of Eovist in Prostate Cancers — 2.01; 1.857; 2.52; 2.212 contrast enhancement ratio (CER) — p=0.0008
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=46 The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
Mucinous Pancreatic Cysts
Primary: Number of Participants With the Changing in Cyst Volume — 6; 12; 5; 4 Participants
Phase 2 N=259 An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 98.1; 97.7; 97.4; 97.2 units on a scale — p=0.2053
Phase 2 N=310 Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores for 32 mg FX006 Versus Placebo — -3.08; -2.50 units on a scale…
Phase 2 N=137 Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Serum Testosterone Levels Reduced to ≤ 2 ng/dL After 4 Weeks of Treatment in Japan — 86.0; 100.0 percentage of participants — p=0.1078
Phase 2 N=232 Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: Duration of Moderate Neurtopenia Post First Chemotherapy Administration — 0.6; 0.6; 0.4; 0.3 days
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
Phase 2 N=85 Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Confirmed Abstinence From Cocaine as Assessed by Treatment Effectiveness Score (TES) — 7; 9 cocaine-negative urines
Phase 2 N=82 Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
Actinic Keratosis
Primary: Number of Adverse Events (AE)/Serious Adverse Events (SAE) as a Measure of Safety and Tolerability up to 20 Weeks — 10; 15; 9; 8 participants
Phase 2 N=23 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Percentage of Patients in Remission at 1 Year — 38.1; 38.8 percentage of participants
Phase 2 N=48 To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 2; 5; 2 Participants
Phase 2 N=30 Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Standard Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Drug Concentration (Cmax) — 238.166; 419.937; 262.523; 534.888 Nanograms per milliliter (ng/mL)
Phase 2 N=99 Safety and Efficacy Study in Patients With Major Depressive Disorder
Depressive Disorder
Primary: Change From Baseline in the Hamilton Depression Rating Scale (HAMD17), on Day 14 and 42 — -10.9; -10.8; -10.3; -18.6 Score on scale
Phase 2 N=46 18-Month Study of Memory Effects of Curcumin
Age-associated Cognitive Impairment · Mild Cognitive Impairment (MCI)
Primary: Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Recall — 19.2; 20.3; 22.4; 22.5 units on a scale — p=0.5
Phase 2 N=30 Fluid Chloride and AKI in Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Change in [TIMP2]*[IGFBP7] Biomarker — 0.015; 0.009 (ng/mL)^2/1000